Asset
ACORAMIDIS
BridgeBio Pharma Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04418024 | phase3 | withdrawn | 2020-10-21 | 2024-03-31 | Eidos Therapeutics, a BridgeBio company | Efficacy and Safety of AG10 in Subjects with Transthyretin Amyloid Polyneurophathy |
| NCT03536767 | phase2 | active_not_recruiting | 2018-08-08 | 2027-07-01 | Eidos Therapeutics, a BridgeBio company | Open-Label Study of AG10 in Patients with Cardiomyopathy |
| NCT03294707 | phase1 | completed | 2017-09-11 | 2018-02-05 | Eidos Therapeutics, a BridgeBio company | Single and Multiple Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of AG10 |
| NCT03458130 | phase2 | completed | 2018-04-27 | 2018-10-05 | Eidos Therapeutics, a BridgeBio company | Study of AG10 in Amyloid Cardiomyopathy |
FDA applications (0)
This company has no applications containing this asset.